HotSpot Therapeutics Presents IRF5 Data

Knight Therapeutics, a biotechnology company, announced the presentation of positive preclinical data from its interferon regulatory factor 5 (IRF5) inhibitor program at the European Society of Endocrinology (EULAR) 2026. The data showed that HotSpot's small molecule IRF5 inhibitors achieved potent, dose-dependent suppression of cytokine production in human immune cells and prevented plasmablast differentiation in B cells, a key driver in systemic lupus erythematosus (SLE). In both mouse and cynomolgus monkey models, the inhibitors demonstrated dose-dependent inhibition of cytokines and mRNA response, confirming pathway-level modulation. Geraldine Harriman, Co-Founder and Chief Scientific Officer of Knight Therapeutics, highlighted the critical role of IRF5 in immune system regulation and the potential for these inhibitors to impact three key inflammatory pathways. This advancement aims to bring forward a novel, orally-administered treatment option for patients with a broad range of autoimmune diseases.